How to Exhibit at #BIO2012
Yesterday, we responded on LinkedIn to the following note: THis is our first BIO conference in June and want to make it a great one. Any hints or helpful suggestions…
Yesterday, we responded on LinkedIn to the following note: THis is our first BIO conference in June and want to make it a great one. Any hints or helpful suggestions…
AOL sells patents to Microsoft. Why? The reasons for AOL selling these patents are pretty clear: Shares of AOL surged as much as 45% Monday, hitting their highest point in…
The past seven days have brought us two very interesting transactions. First, on March 14, Lyon-based Flamel announced their acquisition of St. Louis-based Eclat Pharmaceuticals. The press release contains a…
Earlier this week we learned that Pfizer will return to Biocon rights to biosimilar versions of various insulin derivatives: As of March 12, 2012, all rights licensed to Pfizer will…
The February, 2012 issue of Life Science Leader has a wide-ranging interview with G. Steven Burrill. It's an interesting, insightful read, and we can recommend the interview. Mr. Burrill makes…
UPDATE (21 February) - Here is a decent video interview of Rachel Sherman, head of the Office of Medical Policy for the FDA, on the Biosimilar guidelines: BioCentury This Week Today…
Last week, the NY Times published an interesting article on the cause of Alzheimer's Disease. The article describes experiments in a new mouse model which may confirm, once and for…
Lacerta Bio has returned to cold, windy New York following a solid week in sunny, warm San Francisco. We blogged about last year's JP Morgan Healthcare conference here . For…
Last month, Lacerta Bio celebrated its first full year in existence. In fact, our coming out event was JP Morgan 2011. What have we learned in a year? Probably too…
Happy New Year, everyone! Next week, 2012 kicks off with the madness otherwise knows as JP Morgan, or #JPM12 if you prefer. We blogged about last year's conference here. Last…